Action
Trophic factor.

Status
North American phase II/III trial halted 5/98 after review of data on 300 patients. "This decision was based on an unfavorable risk-to-benefit ratio in these stroke patients treated with Fiblast versus those treated with placebo." European Phase II/III trial was continued. Stroke trials discontinued 10/99. Trials for dermal wounds, peripheral vascular disease, and coronary artery disease ongoing. Trial results unpublished as of 1/2002.

Trial(s)
  = Ongoing
  = Completed

	Fiblast Phase 2	Clinical Safety Trial of Intravenous Basic Fibroblast Growth Factor in Acute Stroke
	Fiblast Phase 3	European-Australian Fiblast (Trafermin) in Acute Stroke

UID: 21